Gilead Sciences (GILD) Cash from Financing Activities (2009 - 2026)
Gilead Sciences' (GILD) quarterly Cash from Financing Activities came in at -$4.2 billion in Q1 2026, down 23.73% YoY from -$5.6 billion in Q1 2025, and down 235.63% on a QoQ basis from -$1.3 billion in Q4 2025.
Gilead Sciences (GILD) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Cash from Financing Activities data on file, last reported at -$4.2 billion in Q1 2026.
- Quarterly Cash from Financing Activities fell 23.73% year-over-year to -$4.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.6 billion (down 55.66% YoY) and the FY2025 annual result came in at -$7.7 billion, down 125.6% from the prior year.
- Cash from Financing Activities fell to -$4.2 billion in Q1 2026, from -$1.3 billion in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $2.3 billion in Q4 2024 to a low of -$4.2 billion in Q1 2026.
- A 5-year average of -$1.6 billion and a median of -$1.5 billion in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 305.64% in 2024, down 168.21% in 2024.
- Tracing GILD's Cash from Financing Activities over 5 years: stood at -$1.6 billion in 2022, then gained by 29.28% to -$1.1 billion in 2023, then soared by 305.64% to $2.3 billion in 2024, then sank by 155.88% to -$1.3 billion in 2025, then plunged by 235.63% to -$4.2 billion in 2026.
- The last three Cash from Financing Activities figures came in at -$4.2 billion (Q1 2026), -$1.3 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.34 Bn |
| Jun 30, 2026 | 2.34 Bn |
| Mar 31, 2026 | -4.24 Bn |
| Mar 31, 2026 | -4.24 Bn |
| Dec 31, 2025 | -1.26 Bn |
| Dec 31, 2025 | -1.26 Bn |
| Sep 30, 2025 | -1.49 Bn |
| Sep 30, 2025 | -1.49 Bn |
| Jun 30, 2025 | -1.57 Bn |
| Jun 30, 2025 | -1.57 Bn |
| Mar 31, 2025 | -3.43 Bn |
| Mar 31, 2025 | -3.43 Bn |
| Dec 31, 2024 | 2.26 Bn |
| Dec 31, 2024 | 2.26 Bn |
| Sep 30, 2024 | -1.38 Bn |
| Sep 30, 2024 | -1.38 Bn |
| Jun 30, 2024 | -2.95 Bn |
| Jun 30, 2024 | -2.95 Bn |
| Mar 31, 2024 | -1.36 Bn |
| Mar 31, 2024 | -1.36 Bn |